DK3194602T3 - Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler - Google Patents

Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler Download PDF

Info

Publication number
DK3194602T3
DK3194602T3 DK15841193.4T DK15841193T DK3194602T3 DK 3194602 T3 DK3194602 T3 DK 3194602T3 DK 15841193 T DK15841193 T DK 15841193T DK 3194602 T3 DK3194602 T3 DK 3194602T3
Authority
DK
Denmark
Prior art keywords
reversion
relationships
procedures
hematopoietic cells
human hematopoietic
Prior art date
Application number
DK15841193.4T
Other languages
English (en)
Inventor
Guy Sauvageau
Keith Richard Humphries
Hans-Peter Kiem
Jalila Chagraoui
Iman Fares
Original Assignee
Univ Montreal
Hutchinson Fred Cancer Res
British Columbia Cancer Agency Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal, Hutchinson Fred Cancer Res, British Columbia Cancer Agency Branch filed Critical Univ Montreal
Application granted granted Critical
Publication of DK3194602T3 publication Critical patent/DK3194602T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15841193.4T 2014-09-18 2015-09-17 Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler DK3194602T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052452P 2014-09-18 2014-09-18
PCT/CA2015/050907 WO2016041080A1 (en) 2014-09-18 2015-09-17 Compounds and methods for enhancing viral gene transfer to human hematopoietic cells

Publications (1)

Publication Number Publication Date
DK3194602T3 true DK3194602T3 (da) 2020-02-17

Family

ID=55532390

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15841193.4T DK3194602T3 (da) 2014-09-18 2015-09-17 Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler

Country Status (13)

Country Link
US (1) US10273503B2 (da)
EP (1) EP3194602B1 (da)
JP (1) JP6795493B2 (da)
CN (1) CN107208111B (da)
CA (1) CA2961535C (da)
DK (1) DK3194602T3 (da)
ES (1) ES2773892T3 (da)
HR (1) HRP20200145T1 (da)
HU (1) HUE048042T2 (da)
LT (1) LT3194602T (da)
PL (1) PL3194602T3 (da)
PT (1) PT3194602T (da)
WO (1) WO2016041080A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017218948A2 (en) * 2016-06-17 2017-12-21 Fred Hutchinson Cancer Research Center Strategies to assess and/or produce cell populations with predictive engraftment potential
WO2018140791A1 (en) 2017-01-27 2018-08-02 Children's Hospital Medical Center Methods of enhancing engraftment activity of hematopoietic stem cells
WO2023286088A1 (en) * 2021-07-16 2023-01-19 Indian Institute Of Science Education And Research Bhopal Methods and compositions for viral vector transduction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
NO941126D0 (no) * 1994-03-25 1994-03-25 Int Digital Tech Inc Multidomenes bevegelsesestimator
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318819A1 (en) 1998-02-05 1999-08-12 Novartis Ag Expanded and genetically modified populations of human hematopoietic stem cells
US20030044978A1 (en) 1998-02-05 2003-03-06 Novartis Corporation Expanded and genetically modified populations of human hematopoietic stem cells
GB2390090A (en) * 2002-06-24 2003-12-31 Bayer Ag Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
WO2003091442A1 (en) * 2002-04-26 2003-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improved chimeric glycoproteins and pseudotyped lentiviral vectors
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
RU2009100930A (ru) 2006-06-14 2010-07-20 Чугаи Сейяку Кабусики Кайся (Jp) Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток
WO2008136656A1 (en) * 2007-05-02 2008-11-13 Erasmus University Medical Center Rotterdam Improved methods and means for lentiviral gene delivery
US8618121B2 (en) * 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
WO2011056739A1 (en) * 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
WO2013045639A1 (en) * 2011-09-29 2013-04-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) LENTIVIRAL VECTORS PSEUDOTYPED WITH MUTANT BaEV GLYCOPROTEINS
TR201909582T4 (tr) * 2012-01-27 2019-07-22 Univ Montreal Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi.
US20150216903A1 (en) * 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
CN106414445B (zh) 2014-04-22 2020-07-03 蒙特利尔大学 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用

Also Published As

Publication number Publication date
CN107208111B (zh) 2021-07-06
CN107208111A (zh) 2017-09-26
EP3194602A1 (en) 2017-07-26
US20180201953A1 (en) 2018-07-19
ES2773892T3 (es) 2020-07-15
JP6795493B2 (ja) 2020-12-02
EP3194602A4 (en) 2017-10-18
LT3194602T (lt) 2020-05-11
JP2017529075A (ja) 2017-10-05
CA2961535C (en) 2024-03-12
CA2961535A1 (en) 2016-03-24
US10273503B2 (en) 2019-04-30
HRP20200145T1 (hr) 2020-05-15
WO2016041080A1 (en) 2016-03-24
HUE048042T2 (hu) 2020-05-28
EP3194602B1 (en) 2019-11-06
PT3194602T (pt) 2020-03-03
PL3194602T3 (pl) 2020-07-27

Similar Documents

Publication Publication Date Title
HK1247636A1 (zh) Rna指導的人類jc病毒和其他多瘤病毒的根除
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
DK3317401T3 (da) Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK3473648T3 (da) Humane antistoffer mod PD-L1
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
CL2016002300A1 (es) Combinaciones de principios activos insecticidas y nematocidas
DK3142637T3 (da) Keratin treatment formulations and methods
DK3041338T3 (da) Landbrugsmæssige endofytplantesammensætninger og fremgangsmåder til anvendelse
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3354661T3 (da) Fuldstændigt humant antistof mod human CD137 og anvendelse deraf
DK3151875T3 (da) Humane lever-scaffolds
DK3198009T3 (da) Onkolytiske tumorvira og anvendelsesfremgangsmåder
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK3220750T3 (da) Oral rehydreringssammensætning og fremgangsmåder dertil
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3188721T3 (da) Humane terapeutika
DK3138048T3 (da) Kodede celler og cellearrays
DK3586821T3 (da) Stamcellestimulerende sammensætninger og metoder
DK3159296T3 (da) Reb til elevator og fremstillingsfremgangsmåde dertil
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf
DK3183201T3 (da) Spilsamling og fremgangsmåde til anvendelse
DK3107902T3 (da) Forbindelser og fremgangsmåder til at hæmme fascin
DK3277948T3 (da) Bølgekraftværk
DK3253766T3 (da) Forbindelser og fremgangsmåder til forebyggelse eller behandling af sansehårscelledød
BR112016026143A2 (pt) os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico.